The Lancet has published a four-paper series on the menopause. Papers two, three and four – Optimising health after early menopause; Promoting good mental health over the menopause transition; and Managing menopause after cancer - are largely in keeping with current international and national guidelines, including NICE guidance. Menopause care should be individualised, and [...]
Professor Linda Cardozo was a Professor of Urogynaecology and Consultant Gynaecologist at King’s College Hospital. She served on the British Menopause Society medical advisory council from 1995 until 2004 and was the first woman to hold the post of BMS Chair, 2001 – 2003. We are pleased to share details of the Linda Cardozo [...]
The Equality and Human Rights Commission (EHRC) has issued new guidance on menopause in the workplace, setting out employers’ legal obligations under the Equality Act 2010, today.There is a need to raise awareness of menopause in the workplace and it is important to have a national platform to support both employers and employees. The EHRC [...]
The DHSC has announced that, since launching the HRT prescription prepayment certificate (PPC) on 1 April last year, more than 500,000 women in England have accessed cheaper HRT, saving hundreds of pounds in prescription charges A key pillar of the first year of England’s Women’s Health Strategy, the HRT PPC has reduced prescription costs [...]
Speaking at a Women’s Health Summit in central London to mark the second year of the Women’s Health Strategy, the Health and Social Care Secretary has named problem periods, women’s health research and support for domestic and sexual abuse victims among the government’s priorities for women’s health in 2024. The 2024 priorities were developed [...]
Mirena is a 52mg Levonorgestrel IUD. Regulatory approval has been received to extend the use of this device, for contraception only, to eight years. There has been no change in the licence for treatment of heavy menstrual bleeding (HMB) (5 years) or for endometrial protection (4 years). We welcome the extended licence for younger [...]
A study recently published in RMD Open, a BMJ publication, suggests that HRT may be associated with an increased risk of rheumatoid arthritis. Rheumatoid arthritis (RA) is more prevalent in women than men. The prospective cohort study used data collected from UK Biobank participants. Whilst the results of the study are interesting, the clinical [...]
There has been much discussion in the media about the licensing of a new treatment option for vasomotor symptoms (hot flushes and night sweats) by the MHRA earlier this month. The BMS would like to provide some clarity with regard to this additional treatment option soon to be available to women. Fezolinetant was licensed [...]
We are delighted to announce the publication of a new Women’s Health Concern factsheet – Epilepsy, the menopause and HRT. This comprehensive new resource, written by Professor Anne MacGregor in collaboration with the medical advisory council of the British Menopause Society, has been reviewed by the national UK charity Epilepsy Action. It addresses several [...]
The BMS is delighted with news that the MHRA has licensed fezolinetant for the treatment of moderate to severe vasomotor symptoms. Vasomotor symptoms (VMS) can have a significant impact on many women, with more than 75% experiencing VMS and a quarter describing their symptoms as severe. A third of women experience long-term symptoms, which [...]
